Name: LGD-4033 100x10mg
Brand: Averlane Labs
Price: 80.00 EUR
Availability: InStock

NOT FOR HUMAN CONSUMPTION

LGD-4033 is an oral, non-steroidal selective androgen receptor modulator (SARM) designed to produce anabolic effects in muscle and bone with comparatively less stimulation of prostate/skin than testosterone. It binds the androgen receptor (AR), recruits co-activators in muscle/bone, and avoids 5-α reduction and aromatization. LGD-4033 is not FDA/EMA-approved; it remains an investigational agent and is prohibited by WADA as an anabolic agent.

Additional Benefits of LGD-4033 Now Under Investigation

Benefit	Key take-aways
1 Lean-mass accrual in humans (short term)	In a 21-day, randomized, placebo-controlled trial in healthy men, dose-dependent increases in fat-free mass (~0.6–1.5 kg) occurred without major fluid retention; strength/power showed favorable trends. <br/><em>Journal of Gerontology: Medical Sciences; JCEM</em>
2 Functional performance	Improvements in leg-press strength and stair-climb power have been reported in small studies, consistent with anabolic signaling translating to function. <br/><em>Medicine & Science in Sports & Exercise</em>
3 Anti-catabolic potential	In preclinical atrophy models (castration, hind-limb unloading), LGD-4033 preserves muscle CSA and reduces ubiquitin-ligase (MAFbx/MuRF1) expression. <br/><em>FASEB Journal; American Journal of Physiology–Endocrinology</em>
4 Bone-anabolic signals	In rodent osteopenia, LGD-class SARMs increase BMD and biomechanical strength, with osteocalcin/ALP rises and limited prostate stimulation. <br/><em>Journal of Bone and Mineral Research</em>
5 Recovery after immobilization/illness (concept)	Early translational work explores post-fracture and post-hospitalization lean-mass restoration with exercise/rehab. <br/><em>Geriatrics & Gerontology International</em>
6 Erythropoiesis (modest)	Androgen-axis engagement may slightly raise hemoglobin/hematocrit, below testosterone’s magnitude, requires monitoring in at-risk patients. <br/><em>Hematology</em>
7 Oral convenience	Once-daily oral dosing with a long half-life supports adherence in trials compared with injectable anabolics. <br/><em>Clinical Pharmacology & Therapeutics</em>
8 Tissue selectivity	Non-steroidal AR binding yields lower sebaceous/prostate stimulation per unit anabolic effect versus 17-α-alkylated androgens. <br/><em>Journal of Pharmacology & Experimental Therapeutics</em>
9 Combination with resistance training	Preliminary data suggest additive gains when paired with structured training and adequate protein intake. <br/><em>Sports Medicine</em>

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

LGD-4033 binds AR → nuclear translocation → ARE-driven transcription. In muscle, it up-regulates mTOR/IGF-1networks and down-regulates atrogenes; in bone, it enhances osteoblast activity and may suppress osteoclastogenesisindirectly. Lack of aromatization/5-α reduction underlies its tissue selectivity vs testosterone.

2.2 Down-stream Biology

Pathway	Functional outcome	Context
AR → mTOR/S6K	↑ protein synthesis, myofiber hypertrophy	Skeletal muscle
AR → Wnt/β-catenin/Osterix	↑ osteoblastogenesis, ↑ BMD	Bone
↓ FoxO/ubiquitin ligases	↓ proteolysis (MAFbx/MuRF1)	Catabolic states
Myostatin/activin crosstalk	Favors anabolic balance	Muscle

3. Pharmacokinetics

Route: Oral.
Half-life: ~24–36 h, allowing once-daily dosing; steady state ~5–7 days.
Absorption/food effect: Good oral bioavailability; minor food effects reported.
Metabolism: Hepatic oxidative and conjugative pathways; high protein binding.
Elimination: Renal/hepatic clearance of metabolites.
Doping detection: Long-term metabolites enable detection weeks after use in anti-doping assays.

4. Pre-clinical and Translational Evidence

4.1 Healthy Volunteers

21-day RCT showed dose-proportional increases in lean mass, small strength/power improvements, and reversible suppression of LH/FSH/testosterone with HDL reduction; liver enzymes were largely within reference in the short term.

4.2 Sarcopenia/Frailty & Orthopedics

Concept studies target older adults and post-fracture patients to accelerate rehabilitation gains; definitive phase-2/3 data are lacking.

4.3 Bone Health

Rodent data demonstrate spine/femur BMD gains and improved three-point bend strength, supporting exploration in osteoporosis or glucocorticoid-induced bone loss.

Evidence quality note: Human data remain short-term and small. Long-term efficacy and safety (CV, hepatic, prostate, psychiatric) are not established.

5. Emerging Clinical Interests

Field	Rationale	Current status
Sarcopenia/aging	Oral anabolic with less prostate/steroid baggage	Early translational
Hip-fracture/immobilization	Lean-mass restoration to speed rehab	Pilot concepts
Cancer/cachexia	Appetite-neutral anabolic (vs ghrelin mimetics)	Pre-clinical/feasibility
Osteoporosis (adjunct)	Bone-anabolic/anti-resorptive balance	Pre-clinical

6. Safety and Tolerability

Endocrine suppression: Dose-dependent LH/FSH and total/free testosterone suppression within 3 weeks; generally reversible over several weeks post-discontinuation.
Lipids: HDL-C reductions (often 10–25%) and occasional ↑ TG/LDL; monitor cardiovascular risk.
Hepatic: Short trials showed minimal median ALT/AST change, but case reports of cholestatic/drug-induced liver injury exist from real-world/“supplement” use, source quality and co-ingestants confound.
Cardiovascular: No outcome data; theoretical risk via atherogenic lipid shifts.
Hematologic: Mild ↑ hematocrit possible, monitor if baseline high.
Other AEs: Headache, nausea, dry mouth, musculoskeletal aches, insomnia/irritability in some users.
Drug interactions: Potential with drugs affecting hepatic enzymes/lipids; avoid concomitant hepatotoxins and pregnancy exposure.

Comparative safety matrix

Concern	LGD-4033	Testosterone (therapeutic)	Enobosarm (ostarine)
Route & t½	Oral; 24–36 h	IM/SC/transdermal; variable	Oral; 24–36 h
Lean-mass gain (short term)	Yes (≈1 kg in 3 wks)	Yes (dose-dependent)	Yes (RCTs in illness/aging)
HPG-axis suppression	Moderate	Marked (exogenous)	Moderate
HDL reduction	Common	Variable	Common (milder)
Prostate/PSA	Low change short-term	Increases possible	Low change
Hepatotoxicity signal	Case reports (real-world)	Low (non-17-α oral)	Low–moderate (case reports exist)

7. Regulatory Landscape

Approvals: None (no medical indication).
Enforcement: FDA warnings against SARM-containing “supplements”; multiple product adulteration recalls.
Sport: WADA-prohibited (S1 Anabolic Agents). Positive tests often arise from contaminated supplements; strict liability applies.
Clinical development: Limited, with no recent pivotal trials publicly reported.

8. Future Directions

Long-term safety studies (lipids, liver, prostate, mood/CNS) with standardized, GMP drug supply.
Elderly/frailty RCTs pairing LGD-4033 with progressive resistance training and protein optimization.
Bone-focused trials (DXA/BCT, microarchitecture).
Biomarker strategy: IGF-1, myostatin, CK, lipid panel, LH/FSH/testosterone, and ctDNA/PSA where appropriate.
Medicinal chemistry: Next-gen SARMs with improved anabolic:androgenic ratio, lipid neutrality, and hepatobiliary safety.

Selected References

Basaria S. et al. Safety, PK/PD, and body-composition effects of LGD-4033 in healthy men (21-day RCT). J Gerontol A Biol Sci Med Sci.
Dalton J.T., Kearbey J.D., et al. Nonsteroidal SARMs: pharmacology and therapeutic prospects. J Med Chem; Endocr Rev.
Gao W., et al. SARMs in muscle and bone, preclinical efficacy and selectivity. J Pharmacol Exp Ther; JBMR.
Evans N.A., Hasenoehrl T. Androgens, erythropoiesis, and cardiovascular risk. Hematology; Circulation Research.
Drug Testing & Analysis / WADA Lab Reports. LGD-4033 long-term metabolites and detection windows.
Case reports/series of SARM-associated liver injury in real-world use. Hepatology Communications; J Clin Transl Hepatol.

LGD-4033 100x10mg

Complete the setup